May 31, 06:29 PM

Inozyme Pharma Tops May Gains as S&P 500 Hits 21x PE Ratio, Underperforms Global Stocks by 12 Points YTD

In May 2025, several stocks posted notable gains, with Inozyme Pharma leading at a 273.1% increase, followed by Navitas Semiconductor at 158.7%, and D-Wave at 127.7%. Other top performers included Dave (+109.4%), Sezzle (+103.7%), and ADC Therapeutics (+100.4%). Major technology companies showed mixed results for the month: Nvidia rose 24%, Tesla 23%, Coinbase 22%, Dell 21%, Meta 18%, Microsoft 16%, AMD 14%, Shopify 13%, Amazon 11%, Adobe 10%, Alphabet 8%, and Netflix 7%. However, year-to-date through May 2025, the performance of large-cap tech stocks was uneven, with Microsoft up 9.2%, Nvidia up 0.6%, Meta up 10.6%, while Apple declined 19.8%, Amazon 6.6%, Google 9.3%, and Tesla 14.2%. The S&P 500 index's price-to-earnings ratio reached 21 times projected earnings over the next 12 months, well above its historical average of 16 times, indicating elevated valuations. Sector-wise, industrials, utilities, and consumer staples gained between 7% and 9% year-to-date, outperforming technology and consumer discretionary sectors, which declined between 2% and 6%. The S&P 500 has increased only 0.5% year-to-date, marking one of the weakest performances since 2010, and has underperformed global stocks excluding the US by 12 percentage points—the largest gap in 32 years, exceeding the disparity seen during the Great Financial Crisis. In contrast, alternative assets such as gold (+25.3%), silver (+14.2%), Bitcoin (+11.8%), and short-term US government bonds (+2.1%) have posted stronger returns. Among the top growth performers in 2025 are Oklo (+148%), Hims (+134%), and ThermoGenesis (+104%). Within the S&P 500, Palantir leads with a 74.2% gain, followed by NRG Energy (+72.8%) and Howmet (+55.3%).

Written with ChatGPT (GPT-4).

Sources

Additional media

Image #1 for story inozyme-pharma-tops-gains-s-p-500-hits-21x-pe-ratio-underperforms-global-stocks-2ad67f14

Image #2 for story inozyme-pharma-tops-gains-s-p-500-hits-21x-pe-ratio-underperforms-global-stocks-2ad67f14

Image #3 for story inozyme-pharma-tops-gains-s-p-500-hits-21x-pe-ratio-underperforms-global-stocks-2ad67f14

Image #4 for story inozyme-pharma-tops-gains-s-p-500-hits-21x-pe-ratio-underperforms-global-stocks-2ad67f14

Image #5 for story inozyme-pharma-tops-gains-s-p-500-hits-21x-pe-ratio-underperforms-global-stocks-2ad67f14

Image #6 for story inozyme-pharma-tops-gains-s-p-500-hits-21x-pe-ratio-underperforms-global-stocks-2ad67f14